Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




Aug
03
Today In Oncology
FDA Approves Radionuclide Therapy Plus ARPI for mAPMN/S Prostate Cancer
ACS Study Quantifies Financial Burden of Cancer in Older Patients
Transplant Consolidation Improves Survival in Primary CNS Lymphoma
Pirtobrutinib Triplet Improves Progression-Free Survival in Previously Treated CLL
NCI Names New CCR Director
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo